Squamous cell carcinoma of the skin: Difference between revisions

Jump to navigation Jump to search
Line 42: Line 42:
*'''[[Squamous cell carcinoma surgical treatment|Surgical treatment]]'''
*'''[[Squamous cell carcinoma surgical treatment|Surgical treatment]]'''
*'''[[Primary Prevention]]'''
*'''[[Primary Prevention]]'''
*'''[[Secondary Prevention''']]
*'''[[Secondary Prevention]]'''


==Future and Investigational treatment strategies==
==Future and Investigational treatment strategies==

Revision as of 22:04, 16 June 2012

For patient information click here

Template:DiseaseDisorder infobox

Squamous cell carcinoma of the skin Microchapters

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Squamous cell carcinoma of the skin from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT Scan

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Squamous cell carcinoma of the skin On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Squamous cell carcinoma of the skin

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Squamous cell carcinoma of the skin

CDC on Squamous cell carcinoma of the skin

Squamous cell carcinoma of the skin in the news

Blogs on Squamous cell carcinoma of the skin

Directions to Hospitals Treating Squamous cell carcinoma of the skin

Risk calculators and risk factors for Squamous cell carcinoma of the skin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2], Raviteja Guddeti, M.B.B.S. [3]

Overview

Historical Aspects

Pathophysiology

Epidemiology and Demographics

Risk Factors

Screening

Causes of Squamous cell carcinoma

Differential Diagnosis

Natural History Complications and Prognosis

History & Symptoms

Physical Examination

Staging

Treatment

Future and Investigational treatment strategies

In 2007, Australian biopharmaceutical company Clinuvel Pharmaceuticals Limited began clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name afamelanotide, formerly CUV1647)[1] to provide photoprotection for organ transplant patients against squamous cell carcinoma of the skin and actinic keratosis.[2][3]

Cetuximab a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced squamous cell carcinoma of the skin, as initially suggested by case reports.

References

  1. "World Health Organisation assigns CUV1647 generic name" (PDF). Clinuvel. 2008. Retrieved 2008-06-17.
  2. Clinuvel » Investors » FAQs
  3. PharmaAsia - Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials

External links


Template:Tumors of bone, cartilage, skin, connective, and soft tissue Template:Respiratory and intrathoracic neoplasia Template:Genital neoplasia Template:Epithelial neoplasms

de:Plattenepithelkarzinom he:קרצינומת תאי קשקש nl:Plaveiselcelcarcinoom


Template:WikiDoc Sources